Sandra L. Phillips - 29 Dec 2023 Form 4 Insider Report for Chemours Co (CC)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
03 Jan 2024, 16:12:54 UTC
Prior SEC filing
12 Dec 2023
Next SEC filing
12 Mar 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Nicole Perez Lengel, Attorney-in-Fact

Key filing fact

Sandra L. Phillips filed Form 4 for Chemours Co (CC) on 03 Jan 2024.

Key facts

  • This page summarizes Sandra L. Phillips's Form 4 filing for Chemours Co (CC).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 03 Jan 2024, 16:12.

Change

  • Previous filing in this sequence was filed on 12 Dec 2023.
  • Current net transaction value: +$25,000.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
16,065
Date
29 Dec 2023
Ownership
Direct
Footnotes
F1
CC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
378
Date
29 Dec 2023
Ownership
By Spouse

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CC transaction Derivative

Stock Units

Award

Transaction value
$25,000
Shares
+793
Change %
+16%
Price
$31.54
Shares after
5,806
Date
29 Dec 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
793
Exercise price
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Includes stock units and dividend equivalent units.

Footnote F2

Units are credited under the Chemours deferred compensation plan for directors and convert one-for-one to Chemours common stock.

Footnote F3

Payable in 2028 per election under the Chemours deferred compensation plan for directors.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .